TrianglePembrolizumab (Keytruda) (NCT01174121)
Pembrolizumab (Keytruda) trial for Metastatic Colorectal Cancer (NCT01174121). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 18–72 with metastatic gastrointestinal, hepatobiliary, genitourinary, breast, ovarian/endometrial or endocrine cancers resistant to standard treatment. Prior-treatment rules vary by cancer. Tumor removal must be feasible for cell collection.
The idea: grow tumor-infiltrating immune cells, then return them after lymphodepleting chemotherapy, with high-dose aldesleukin. Pembrolizumab starts before cell infusion or after progression, depending on the arm. Two earlier arms are closed.
This phase 2 study plans 332 patients. Steven Rosenberg leads the NCI study at the NIH Clinical Center in Bethesda, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.